BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BC Extra | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation...
BC Extra | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

China’s Joint Procurement Office announced steep price cuts for companies that won the tender bids for 25 drugs in the nationwide expansion of its pilot program for centralized procurement of generic and off-patent originator drugs....
BC Week In Review | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Dec. 6 in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported...
BC Extra | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Thursday in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported significantly...
BC Extra | Sep 12, 2018
Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
BC Innovations | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
BC Week In Review | Oct 24, 2016
Clinical News

Propagermanium and irbesartan: Interim Phase II data

Interim data from 11 CKD patients with proteinuria who completed the 90 mg dose level in the dose-escalation part A of an open-label, Australian Phase II trial showed DMX-200 led to about a >=50% reduction...
BC Week In Review | Sep 12, 2016
Clinical News

Sparsentan: Phase II data

Top-line combined data from the 3 sparsentan cohorts in the double-blind, international Phase II DUET trial in 96 evaluable patients with focal segmental glomerulosclerosis showed that once-daily oral sparsentan met the primary endpoint of reducing...
BC Extra | Sep 7, 2016
Clinical News

Retrophin jumps on Phase II FSGS data

Retrophin Inc. (NASDAQ:RTRX) rose $4.49 (28%) to $20.81 on Wednesday after it said combined data from the three cohorts of the Phase II DUET study showed sparsentan ( RE-021 ) met the trial's primary endpoint to treat...
Items per page:
1 - 10 of 65